Clinical trials: Haematologic Neoplasms, active
EBV-associated Haematologic Neoplasms
KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
The primary objectives of this study is to evaluate the tolerability and safety of KSD-101 in Patients with EBV-associated haematologic neoplasms, observe the dose-limiting toxicity (DLT) and and to explore the maximum tolerated…
- Trial name
- NCT05635591
- Testing
- Autologous monocyte - derived DCs pulsed with EBV antigen
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Tongji Hospital
Haematologic Neoplasms
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in…
- Trial name
- NCT07064122
- Testing
- AZD2962
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Geriatric, Haematologic Neoplasm
Feasibility of Physical Activity in Older Adults With Haematological Malignancies: ACCES Study
The aim of this study is to implement a simple and unsupervised home-based physical activity (PA) program for cancer patients in 2 oncogeriatric units in Toulouse Hospital (day hospital and week hospital).
- Trial name
- ACCES (NCT06102876)
- Testing
- Physical activity (PA) program
- Where
- France
- Volunteers
- 69 people
- Sponsor
- University Hospital, Toulouse
Haematologic Neoplasm
Characteristics and Outcomes of Patients With Hematological Malignancies
The pattern of hematological malignancies (HMs) in developing countries and developed countries differs. Among the different types of cancers, leukemia, lymphoma, and multiple myeloma appear to have greatly increased in frequency.
- Trial name
- NCT06402175
- Testing
- follow up
- Volunteers
- 100 people
- Sponsor
- Assiut University
Multiple Myeloma, Neoplasms
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
This is a phase 1/2, open-label study designed to assess the safety and clinical activity of different belantamab mafodotin doses in combination with lenalidomide, dexamethasone and nirogacestat in patients with transplant…
- Conditions
- Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal
- Trial name
- NCT05573802
- Testing
- Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone
- Where
- 2 sites in Greece
- Volunteers
- 36 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma, Multiple Myeloma in Relapse
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
This is a phase 1/2, open label, single-center study designed to assess the safety and preliminary clinical activity of different belantamab mafodotin doses in combination with daratumumab, pomalidomide, and dexamethasone (DPd)…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal
- Trial name
- NCT05581875
- Testing
- Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide
- Volunteers
- 48 people
- Sponsor
- Hellenic Society of Hematology